A Phase 2 interventional study of ERB-041 in Endometriosis, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 46 sites in United States. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2015-05-01.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 2, Interventional, and Treatment
The purpose of this investigational study is to determine if a study medication is safe and effective in reducing the symptoms associated with endometriosis; if the study medication reduces the need for pain medication for endometriosis symptoms; and if the study medication improves a participant's ability to carry out daily activities. Qualified participants will receive no cost treatment, which may include study-related examinations, diagnostic procedures including a Pap smear, laboratory testing, and a mammogram (aged 40-45). Qualified participants will also receive study medication at no cost. As a participant, the study volunteer may also experience the satisfaction of knowing she is helping the advancement of women's health care.
925 studies on the registry are indexed under Endometriosis; 264 are open to participants now.
This study's enrollment of 200 is above the median of 65 across 539 interventional studies indexed under Endometriosis.
Browse Endometriosis studies →Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.
First submitted before Wyeth became part of Pfizer.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
To assess the effects and to compare the safety profile of an investigational
medication on the relief of endometriosis-related symptoms.
Clinical and subject assessment of symptoms related to endometriosis and the
use of analgesia to relieve symptoms.
This study is completed, as verified in Dec 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ERB 041
Wyeth is now a wholly owned subsidiary of Pfizer →